Literature DB >> 27711378

A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies.

Stacey E Rudd1, Peter Roselt2, Carleen Cullinane3, Rodney J Hicks4, Paul S Donnelly1.   

Abstract

A squaramide ester derivative of desferrioxamine B (H3DFO) that is compatible with aqueous solvents and does not induce antibody aggregation is used to attach the siderophore to the antibody trastuzumab. The new conjugates were radiolabeled with zirconium-89 to give complexes that are more resistant to ligand exchange when compared to currently used H3DFO derivatives and result in high quality positron emission tomography images in mouse models of HER2 positive breast cancer.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27711378     DOI： 10.1039/c6cc05961a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  20 in total

1.  Investigation of the complexation of natZr(iv) and 89Zr(iv) by hydroxypyridinones for the development of chelators for PET imaging applications.

Authors:  F Guérard; M Beyler; Y-S Lee; R Tripier; J-F Gestin; M W Brechbiel
Journal:  Dalton Trans       Date:  2017-04-05       Impact factor: 4.390

2.  Multifunctional Desferrichrome Analogues as Versatile 89Zr(IV) Chelators for ImmunoPET Probe Development.

Authors:  Casey J Adams; Justin J Wilson; Eszter Boros
Journal:  Mol Pharm       Date:  2017-07-19       Impact factor: 4.939

3.  Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.

Authors:  Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal:  Inorg Chem       Date:  2020-11-10       Impact factor: 5.165

Review 4.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

5.  A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas
Journal:  Dalton Trans       Date:  2018-09-04       Impact factor: 4.390

6.  Pyrocinchonimides Conjugate to Amine Groups on Proteins via Imide Transfer.

Authors:  Mark B Richardson; Kristin N Gabriel; Joseph A Garcia; Shareen N Ashby; Rebekah P Dyer; Joshua K Kim; Calvin J Lau; John Hong; Ryan J Le Tourneau; Sanjana Sen; David L Narel; Benjamin B Katz; Joseph W Ziller; Sudipta Majumdar; Philip G Collins; Gregory A Weiss
Journal:  Bioconjug Chem       Date:  2020-04-30       Impact factor: 4.774

7.  Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

Authors:  L Allott; C Da Pieve; J Meyers; T Spinks; D M Ciobota; G Kramer-Marek; G Smith
Journal:  Chem Commun (Camb)       Date:  2017-07-27       Impact factor: 6.222

8.  Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection.

Authors:  Eric Berg; Herman Gill; Jan Marik; Annie Ogasawara; Simon Williams; Guus van Dongen; Daniëlle Vugts; Simon R Cherry; Alice F Tarantal
Journal:  J Nucl Med       Date:  2019-09-27       Impact factor: 10.057

9.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

10.  A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.

Authors:  Elaheh Khozeimeh Sarbisheh; Akam K Salih; Shvan J Raheem; Jason S Lewis; Eric W Price
Journal:  Inorg Chem       Date:  2020-07-28       Impact factor: 5.165
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.